Charles S. Berenson MD
Charles S. Berenson
MD
Professor of Medicine
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Immunology; Infectious Disease
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
View this physician on UBMDProfessional Summary:
My patient care and teaching responsibilities are centered at the Veterans Administration hospital where I care for hospitalized patients and maintain an active outpatient clinic. I enjoy teaching medical students and residents in both lecture and small group settings. In addition, my laboratory is open to interested undergraduate, graduate and medical students and residents seeking to gain a research experience.
Research interests of my laboratory focus on two key areas of the function of specialized immune cells called macrophages. Our first area of interest concentrates on the immunologic roles of mammalian macrophage gangliosides. Gangliosides are unique molecules that hold diverse regulatory roles as receptors and as mediators of cell differentiation in cells of most species. Our studies encompass ganglioside regulation of macrophage inflammatory responses, ganglioside-associated alterations of the architecture of macrophage cell membranes in HIV-infected individuals, and the function of macrophage gangliosides as receptors for bacterial pathogens and toxins. This work will lead to a better understanding of mechanisms of macrophage activation, to permit manipulation of host immune responses.
Our second area of interest centers on the regulation of inflammatory responses of human alveolar macrophages by respiratory bacterial pathogens and bacterial antigens that contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). Studies encompass defining the repertoire of inflammatory mediators of human alveolar and blood-derived macrophages regulated by bacterial pathogens and characterizing bacteria-regulated immunologic properties of macrophages, in patients with COPD. These investigations into fundamental mechanisms of dysfunctional immune responses of macrophages underlying the progression of COPD are providing the basis for designing novel and more effective therapies.
Education and Training:
- Fellowship, Yale University School of Medicine (1987)
- Residency, Internal Medicine Residency, University of Michigan Medical School (1983)
- MD, University at Buffalo (1980)
Employment:
- Residency Program Director, Infectious Diseases (2000-2023), Medicine, University at Buffalo Jacobs School of Medicine & Biomedical Sciences
Awards and Honors:
- Louis A. and Ruth Siegel Award for Excellence in Teaching (2015)
- Clinical Teaching Excellence Award (2011)
- "White Coat" Award for Teaching Excellence (2002)
- Department of Medicine Research Award (2001)
- UB Department of Medicine Research Award (2001)
- "White Coat" Award for Teaching Excellence (1997)
- Clinical Teaching Excellence Award (1992)
Research Expertise:
- Haemophilus influenzae pathogenesis
- Immunoregulatory roles of macrophage ganglioside
- Role of alveolar macrophages in the pathogenesis of respiratory tract infections
Grants and Sponsored Research:
- May 2022–December 2023
Expanded Access Program of SER-109 in the Treatment of Adults with Recurrent Clostridioides Difficile Infection (RCDI)
Seres Therapeutics
Role: Principal Investigator - March 2018–March 2023
Efficacy of the toxin LT-IIc as a specific cytotoxic agent for human basal B triple-negative breast cancer. (Terry Connell – PI)
DoD
Role: Co-Investigator - June 2017–June 2022
ECOSPOR IV: An Open-Label Extension of Study SERES-012 Evaluating SER-109 In Adult Subjects With Recurrent Clostridium difficile Infection - Seres Therapeutics, Inc.
Seres Therapeutics
Role: Principal Investigator - March 2017–March 2020
ECOSPOR III- A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of Clostridium difficile – Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI. Seres Therapeutics, Inc
Role: Principal Investigator - March 2014–March 2020
Roflumilast modulation of macrophage function in exacerbation-prone COPD
Forest Laboratories/Astra Zeneca
Role: Principal Investigator - March 2013–March 2018
Re-activating Memory T-cells in the Microenvironment of Human Tumors. (Richard Bankert - PI)
Role: Co-Investigator - March 2010–March 2013
Enhancing Nrf2 by Sulforaphane Treatment COPD as a Novel Interventional Strategy
NHLBI
Role: Co-Investigator - March 2010–March 2013
Enhancing Nrf2 by Sulforaphane Treatment in9/10- COPD as a Novel Interventional Strategy- Ancillary study
NHLBI
Role: Co-Investigator - September 2005–August 2010
Innate immunity and Exacerbations of COPD.
National Heart, Lung & Blood Institute
Role: Co-Principal Investigator - March 2002–March 2006
Open-label study evaluating the effect of tenofovir disoproxil fumarate on methadone pharmacokinetics in opiate-maintained subjects
Gilead Sciences
Role: Co-Investigator - March 2001–March 2005
Effects of tipranavir/ritonavir in the pharmacokinetic characteristics of nucleoside and non-nucleoside RTI therapy in HIV subjects
Boehringer Ingelheim.
Role: Co-Investigator - March 2000–March 2004
Haemophilus antigen regulation of inflammation in COPD
NHLBI
Role: Co-Principal Investigator - March 1995–March 1998
Immunomodulation of Macrophage Migration by Macrophage Gangliosides
VA- Merit Review
Role: Principal Investigator - March 1994–March 1995
Efficacy of Passive Immunization in the Prevention of Infection due to Klebsiella Species and Pseudomonas aeruginosa
VA Cooperative Study No. 316B
Role: Principal Investigator - March 1991–March 1994
Immunomodulation of MIF by Macrophage Gangliosides
VA Merit Review
Role: Principal Investigator - March 1990–March 1993
Immunomodulation of MIF by Macrophage Gangliosides - Research Associate Award. VA Career Development 1990
Research Associate Award VA Career Development 1990
Role: Principal Investigator - March 1987–March 1990
Purification and Immunoregulatory Properties of Macrophage Gangliosides - Associate Investigator Award. VA Career Development
Associate Investigator Award VA Career Development
Role: Principal Investigator - March 2022
Alveolar macrophage dysregulation in the pathogenesis of Gulf War Respiratory Illness
VA Merit Review
Role: Principal Investigator - March 2019
The Network Biology of Pathogen-Host Interactions Driving Exacerbation in COPD Department of Defense PRMRP - (Sanjay Sethi - PI
DoD
Role: Co-Investigator
Journal Articles:
- Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. (2006) Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis (Jan)
- Berenson CS, Hohmann E, Korman L, Louie T, Sims MD, Pullman, Cohen SH, Oneto C, Wang E, David, Asli, De A, Hasson, BR, McGovern BH, Moltke L, Lee C. (2023) Prevalence of comorbidities and Clostridioides difficile recurrence in ECOSPOR III. Clin Infect Dis. 77:1504-1510 (Mar)(77): 1504-1510. doi:10.1093/cid/ciad448
- Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL, Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L. (2023) Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: A phase 3, open-label, single-arm trial. JAMA Netw Open (Feb), 6: 6(2):e2255758.. doi:doi: 10.1001
- Garey KW, Jo J, Gonzales-Luna AJ, Lapin B, Deshpande A, Wang E, Hasson B, Pham SV, Huang SP, Reese PR, Wu H, Hohmann E, Feuerstadt P, Oneto C, Berenson CS, Lee C, McGovern B, von Moltke L. Improved health-related quality of life of patients with recurrent Clostridioides difficile infection with investigational oral microbiome therapeutic, SER-109 in a randomized phase 3 trial. JAMA Netw Open. 2023 Jan 3;6(1):e2253570. doi:10.1001. (2023) (Jan)
- Hassan S, Berenson CS. A novel case of empyema necessitans caused by Mycobacterium xenopi. BMJ Case Reports, 15:e245953. doi: 10.1136/bcr-2021-245953, 2022. (2022) (Mar)
- Loria SJ, Siddiqui NN, Gary JM, Bhatnagar J, Bollweg B, Ahmed B, Berenson CS. BK virus associated with small cell carcinoma of bladder in a renal transplant patient. BMJ Case Reports, 15:e244740. doi: 10.1136/bcr-2021-244740, 2022. Role: corresponding/senior author, wrote and edited manuscript, experimental design and concept. (2022) (Mar)
- Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, Wu H, Auninš JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 20;386:220-229, 2022. (2022) (Jan)
- Sidhaye V, Holbrook JT, Burke A, Sudini KR, Sethi S, Criner GJ, Fahey JW, Berenson CS, Jacobs MR, Thimmulappa R, Wise RA, Biswal A. Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. Respir Res, 20:190. doi: 10.1186/s12931-019-1164-1, 2019. (2019) Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. , 20:190. Respir Res (Mar), 20: 190. doi:doi: 10.1186/s12931-019-1164-1, 2019.
- Sumon ZE, Berenson CS, Sellick JA, Bulman ZP, Tsuji BT, Mergenhagen KA, Sellick, Jr JA. (2019) Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study. Infect Dis (Lond) (Feb)1-6.
- Shenoy GN, Loyall J, Berenson CS, Kelleher RJ, Iyer V, Balu-Iyer SV, Odunsi K, Bankert RB. (2018) Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. J Immunol (Dec), 201(12): 3750-3758.
- Kurtzhalts KE, Mergenhagen KA, ManoharF A, Berenson CS. (2017) Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane/tazobactam. BMJ Case Reports (Mar)(bcr2016217005.) doi:10.1136/bcr-2016-217005, 2017
- Wise RA, Holbrook JT, Criner G, Sethi S, Rayapudi S, Sudini KR, Sugar EA, Burke A, Thimmulappa R, Singh A, Talalay P, Fahey JW, Berenson CS, Jacobs MR, Biswal S. (2017) Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. Correction. PLoS One (Mar), 12(3): 0175077-0175077.
- Brotzki CR, Mergenhagen KA, Bulman ZP, Tsuji BT, Berenson CS. (2016) Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing. BMJ Case Rep (Oct), 2016.
- Berenson CS, Kruzel RL, Sethi S. (2016) The Impact of Exogenous Factors on Respiratory Pathogen-Induced Innate Alveolar Macrophage Responses in COPD. Immunol Invest (Feb), 45(2): 130-147.
- Marks LR, Dodd H, Russo TA, Berenson CS. (2016) Burkholderia ginsengisoli bacteraemia: emergence of a novel pathogen. BMJ Case Rep (Feb), 2016.
- Kelleher RJ, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, Iyer V, Fathallah AM, Berenson CS, Wallace PK, Tario J, Odunsi K, Bankert RB. (2015) Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. Cancer Immunol Res (Nov), 3(11): 1269-1278.
- Berenson CS, Kruzel RL, Wrona CT, Mammen MJ, Sethi S. (2015) Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms. PLoS One (Sep), 10(9): 0134209-0134209.
- Berenson CS. (2015) Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine dependent arrest in the T cell signaling cascade. Cancer Immunol Res (Jan), 3: 1269-1278.
- Berenson CS, Kruzel R., Eberhardt E., Dolnick R., Minderman H., Wallace P., Sethi S. (2014) Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax (Sep), 69(9): 811-818.
- Shon AS, Berenson CS. (2013) Pseudomonas aeruginosa intrapetrous internal carotid artery mycotic aneurysm--a complication of mastoiditis: first reported case. BMJ Case Rep (Jul), 2013.
- Shon AS, Berenson CS. (2013) Pseudomonas aeruginosa intrapetrous internal carotid artery mycotic aneurysm: a complication of mastoiditis. British Med Journal Case Reports (Jan)
- Berenson CS, Nawar HF, Kruzel RL, Mandell LM, Connell TD. (2013) Ganglioside-binding specificities of E. coli enterotoxin LT-IIc: Importance of long-chain fatty acyl ceramide. Glycobiology (Jan), 23(1): 23-31.
- Bertelle-Ibrahim LA, Murphy TF, Kirkham C, Parameswaran GI, Berenson CS. (2013) Nontypeable Haemophilus influenzae infective endocarditis in a renal transplant recipient: Compromised host or virulent strain?. British Med Journal Case Reports (Jan)
- Berenson CS, Desai H., Eberhardt E., Sethi S. (2013) Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. Journal of Infectious Diseases (Jan), 208(12): 2036-2045.
- Berenson CS, Kruzel RL, E. Eberhardt E, Sethi S. (2013) Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis (Jan)
- Nawar HF, Berenson CS, Hajishengallis G, Takematsu H, Mandell L, Clare RL, Connell TD. (2010) Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the nontoxic mucosal adjuvant LT-IIb(T13I). Clin Vaccine Immunol (Jun), 17(6): 969-978.
- Berenson CS, Nawar, HF, Yohe HC, Castle SA, Ashline DJ, Reinhold VN, Hajishengallis G, Connell TD. (2010) Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I). Glycobiology (Jan)
- Berenson CS, Nawar HF, Yohe HC, Castle SA, Ashline DJ, Reinhold VN, Hajishengallis G, Connell TD. (2010) Mammalian cell ganglioside-binding specificities of E. coli enterotoxins LT-IIb and variant LT-IIb(T13I). Glycobiology (Jan), 20(1): 41-54.
- Nawar HF, Berenson CS, Hajishengallis G, Takematsu H, Mandell L, Connell TD. (2010) Binding to gangliosides containing N-acetylneuraminic acid is sufficient to mediate the immunomodulatory properties of the mucosal adjuvant LT-IIb(T13I). Clin Vaccine Immunol (Jan)
- Bhatti Z, Berenson CS. (2007) Adult systemic cat scratch disease associated with therapy for hepatitis C. BMC Infectious Diseases (Jan)
- Berenson CS, Wrona CT, Grove LJ, Maloney J, Garlipp MA, Wallace PK, Stewart CS, Sethi S. (2006) Impaired Alveolar Macrophage Response to Haemophilus Antigens in Chronic Obstructive Lung Disease. Am J Resp Crit Care Med (Mar), 174(1): 31-40.
- Tomilo DL, Smith PF, Ogundele AB, Difrancesco R, Berenson CS, Eberhardt E, Bednarczyk E, Morse GD. (2006) Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy (Mar), 26(3): 341-346.
- Tomilo DL, Smith PF, Ogundele AB, DiFrancesco R, Berenson CS, Eberhardt E, Bednarczyk E, Morse GD. (2006) Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppressionin healthy volunteers. Pharmacotherapy (Jan), 26(3): 341-346.
- Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. (2006) Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Resp Crit Care Med (Jan)
- Berenson CS, Garlipp M.A., Grove L.L., Maloney J., Sethi S. (2006) Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. Journal of Infectious Disease (Jan), 194(10): 1375-1384.
- Sethi S, Maloney J., Grove L., Wronta C.T., Berenson CS. (2006) Airway inflammation and bronchial bacterial colonization in ex-smokers with COPD. American Journal of Respiratory and Critical Care Medicine (Jan), 173(9): 991-998.
- Berenson CS, Wrona CT, Grove LJ, Maloney J, Garlipp MA, Wallace PK, Stewart CS, Sethi S. (2006) Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Resp Crit Care Med (Jan)
- Berenson CS, Murphy TF, Wrona, C.T., Sethi S. (2005) Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage cytokines. Infection and Immunity (Jan), 73(5): 2728-2735.
- Berenson CS,Murphy TF, Wrona CT, Sethi S. (2005) Outer membrane protein P6 of nontypeable Haemophilus influenzae is a potent and selective inducer of human macrophage proinflammatory cytokines. Infection and Immunity (Jan)
- Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. (2004) The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy (Nov), 24(11): 1508-1514.
- Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. (2004) The influence of St. John‘s wort on the pharmacokinetics and protein bindingof imatinib mesylate. Pharmacotherapy (Jan), 24(11): 1508-1514.
- Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ, Palic B, Schur JL, Buggé CJ, Ljungqvist A, Espinosa O, Hewitt RG. (2004) The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol (Jan), 44(3): 293-304.
- Smith PF, Kearney BP, Liaw S, Cloen D, Bullock JM, Haas CE, Yale K, Booker BM, Berenson CS, Coakley DF, Flaherty JF. (2004) Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamicsof total, R-, and S-methadone. Pharmacotherapy (Jan), 24(8): 970-977.
- Shelton MJ, Giovanniello AA, Cloen D, Berenson CS, Keil K, DiFrancesco R, Hewitt RG. (2003) Effects of didanosine formulations on the pharmacokinetics of amprenavir. Pharmacotherapy (Jan), 23(7): 835-842.
- Berenson C, Sayles KB, Ye S, Reinhold BB, Reinhold VN, Yohe HC. (2003) A conserved ceramide motif present in murine and human mononuclear cell glycosphingolipids. Journal of Lipid Research (Jan)
- Berenson CS, Sayles KB, Huang J, Reinhold VN, Yohe HC. (2003) Preferential binding of ganglioside-adherent nontypeable Haeomphilus influenzae to neolacto core structures of respiratory (HEp-2) cells. FEMS Immunol Med Microbiol (Jan), 45: 171-182.
- Berenson CS, Gallery MA, Smigiera JM, Rasp RH. (2002) The role of ceramide of human macrophage gangliosides in activation of human macrophages. Journal of Leukocyte Biology (Jan), 72: 492-502.
- Zhu Y, Srivatana U, Ullah A, Marhaba A, Berenson CS, Lance P. (2001) Expression of ß-galactoside a2,6-sialyltransferase antisense DNA in human colonic (HT29) cells. Biochim Biophys Acta (Mar), 1536: 148-160.
- Chitre MM, Berenson CS. (2001) Idiosyncratic rifabutin induced leukopenia and SIADH. Pharmacotherapy (Mar), 21: 493-497.
- Berenson CS, Rasp RH, Gau J-T, Ryan JL, Yohe HC. (2001) Differences in splenic B lymphocyte ganglioside expression and accessibility in normal and endotoxin-hyporesponsive mice. Journal of Leukocyte Biology (Jan), 69: 969-976.
- Yohe, HC, Wallace PK, Berenson CS, Ye S, Reinhold BB, Reinhold VN. (2001) The major glycolipids of human peripheral blood monocytes/macrophages; absence of ganglio series structures. Glycobiology (Jan), 11: 831-841.
- Farooqui MA, Berenson C, Lohr JW. (1999) Mycobacterium Marinum Infection in a Renal Transplant Recipient. Transplantation (Jan), 67(11): 1495-1496.
- Berenson CS, Gallery MA, Katari MS, Foster EW, Pattoli MA. (1998) Gangliosides of mononuclear phagocytes of adults with AIDS show reduced surface accessibility. J Leukoc Biol (Mar), 64: 311-321.
- Fakih MG, Murphy TF, Pattoli MA, Berenson CS. (1997) Specific binding of Haemophilus influenzae to minor gangliosides of human respiratory epithelial cells. Infect Immun (May), 65(5): 1695-1700.
- Smith TJ, Sempowski GD, Berenson CS, Cao HJ, Wang H-S, Phipps RP. (1997) Human thyroid fibroblasts exhibit a distinctive phenotype in culture: Characteristic ganglioside profile and functional CD40 expression. Endocrinol (Mar), 138: 5576-5588.
- Berenson CS, Patterson MA, Pattoli MA, Murphy TF. (1996) A monoclonal antibody to human macrophage gangliosides inhibits macrophage migration. J Leukoc Biol (Mar), 59(3): 371-379.
- PiscatelliF JJ, Cohen SA, Berenson CS, Lance P. (1995) Determinants of differential liver colonizing potential of variants of the MCA-38 murine colon cancer cell line. Clin Exp Metastasis (Mar), 13: 141-150.
- Fakih M, Barden GG, Oakes C, Berenson CS. (1995) Aspergillus granulosus infection in a cardiac transplant patient. J Clin Micro (Mar), 33: 471-473.
- Berenson CS, Smith TJ. (1995) Human orbital fibroblasts in culture express ganglioside profiles distinct from those in dermal fibroblasts. J Clin Endocrinol Metab (Mar), 80: 2668-2674.
- Berenson CS, Patterson MA, MiqdadiF J, Lance P. (1995) n-Butyrate mediation of ganglioside expression of human and murine cancer cells demonstrates relative cell specificity. Clin Sci (Mar), 88: 491-499.
- Mangi RJ, Peccerillo KM, Ryan J, Berenson C, Greco T, Thornton G, Andriole VT. (1992) Cefoperazone vs. ceftriaxone monotherapy of nosocomial pneumonia. Diag Microbiol Infect Dis (Mar), 15: 441-447.
- Shah S, Lance P, Smith TJ, Berenson CS, Cohen SA, Horvath P, Lau JT, Baumann H. (1992) n-Butyrate reduces the expression of ß-galactoside ?2-6-sialyl transferase in Hep G2 cells. J Biol Chem (Mar), 267: 10652-10658.
- Berenson CS, Ryan JL. (1991) Macrophage gangliosides inhibit mitogen-induced lymphocyte proliferation. J Leukoc Biol (Mar), 50: 393-401.
- Yohe HC, Berenson CS, Cuny CL, Ryan JL. (1990) Altered B cell membrane architecture indicated by ganglioside accessibility in C3H/HeJ mice. Infect Immun (Mar), 58: 2888-2894.
- Berenson CS, Yohe HC, Ryan JL. (1989) Factors mediating LPS-induced ganglioside expression in murine peritoneal macrophages. J Leukoc Biol (Mar), 45: 221-230.
- Berenson CS, Bia FJ. (1989) Propionibacterium acnes causes post-operative brain abscesses unassociated with foreign bodies. Neurosurgery (Mar), 25: 130-134.
- Berenson CS, Mangi RJ. (1988) Haemophilus aphrophilus sternal osteomyelitis. Southern Med J (Mar), 81: 1593-1594.
- Yohe HC, Cuny CL, Berenson CS, Ryan JL. (1988) Comparison of thymocyte and T lymphocyte ganglioside from C3H/HeN and C3H/HeJ mice. J Leukoc Biol (Mar), 44: 521-528.
- Mangi RJ, Ryan JL, Berenson CS. (1988) Cefoperazone vs. ceftazidime as monotherapy for nosocomial pneumonia. Am J Med (Mar), 85: 44-48.
- Berenson CS, Dobuler KJ, Bia FJ. (1987) Fever, petechiae, pulmonary infiltrates in an immunocompromised Peruvian man. Yale J Biol Med (Mar), 60: 437-455.
- Ryan JL, Berenson CS, Greco TP, Mangi RJ, Sims M, Thornton GF, Andriole VT. (1987) Oral ciprofloxacin in resistant urinary tract infections. Am J Med (Mar), 82 Suppl. 4A: 303-306.
- Berenson CS, Bia FJ. (1986) Fever, frontal sinus mass, and CSF pleocytosis in a 44 year-old man. Yale J Biol Med (Mar), 59: 613-620.
Books and Book Chapters:
- Berenson CS. (2008) In: Bacterial Growth and Metabolism.
Abstracts:
- Berim I., Wrona C., Eberhardt E., Berenson CS, Palaniyar N., Sethi S. (2012) Relationship Of Bronchoalveolar Lavage Levels Of Surfactant Proteins A And D In COPD To Exacerbation Susceptibility, Severity Of Airflow Obstruction And Current Tobacco Smoke Exposure. ATS International Conference, San Francisco, CA, (May)
- Parameswaran GI, Murphy TF, Yin J., Grove L., Eberhardt E., Berenson CS, Sethi S. (2012) Species Specific Susceptibility To Bacterial Colonization And Exacerbation In COPD. ATS International Conference, San Francisco, CA, (May)
- Sethi S, Berenson CS, Clare R.L., Eberhardt E., Wrona C. (2011) Association Of Impaired Innate Immune Responses Of COPD Alveolar Macrophages With Toll-Like Receptor Polymorphisms. ATS International Conference, Denver, CO, (May)
Professional Memberships:
- American Association of Immunologists (2020–present)
- American College of Physicians (2000–present)
- American Society for Microbiology (2000–present)
- Infectious Diseases Society of America (2000–present)
Presentations:
- "Complications of TNF-alpha inhibition" Catholic Health System Grand Rounds (2022)
- "ECOSPOR-III: A phase 3 double-blind, placebo-controlled randomized trial of SER-109 an investigational microbiome therapeutic for recurrent Clostridioides difficile infection" Society for Hospital Medicine (2022)
- "Microbiome restoration in Clostridioides difficile colitis" UB Microbiome Center (2022)
- "Restoration of microbiome for recurrent Clostridioides difficile infection" WNY American Society for Microbiology Symposium (2022)
- "A Tale of Two Toxins" UB Grand Rounds (2018)
- "Toxin mediated infections" Catholic Health System Grand Rounds (2016)
- "Fever of Unknown Origin" UB Gand Rounds (2015)
Service Activities:
- Department Research Forum - Judge (2022–present)
- Physical Examination course- 2nd year medical students (2022–present)
- Grant Reviewer: 2019 Study section – DoD Congressionally Directed ‘Gulf War Illness Research Program - Reston, VA 2012, 2014, 2016, 2017, British Lung Foundation 2018 2019 Long Fonds, Netherlands 2017-2022 VA /Internal Reviewer – 15 proposals over the past 5 years (2022–present)
- UB 1995-1997 University Student Research Committee Hospital/VAMC: 1990-1994 Animal Studies Committee 1990-1995 Laboratory Utilization Subcommittee 1992-1994 Animal Studies Committee Chairman 1993-1996 Research and Development Committee 1994-1997 Radiation Safety Committee 1996-1997 Ad hoc Committee on Interim Research Funding 1996-1999 Human Studies Committee 1997-2002 Clinical Microbiology Laboratory Committee 2001-2004 Research and Development Committee 2010-present Safety Committee Medical School Service: 1995-1997 Biomedical Research Committee 1996-1998 University Office of Medical Computing Department of Medicine Representative 1999-2000 Chair, Internal Accreditation Review Committee 2000-2001 Department of Microbiology Graduate Preliminary Exams 2003-2007 Research Promotions Committee 2006-2007 Research Promotions Committee, Chair 2019-present Physical Examination course- 2nd year medical students Voluntary Medical School activity Department Service: Department of Medicine: 1997-2000 Residency Interviews 2004-2010 Website Committee-Chair 2009-2012 Promotions Committee 2017-Present Department Research Forum - Judge Infectious Diseases Division: 1994-present I.D. Fellowship Selection Committee 1996-2001 Clinical Conference Course Coordinator 1999-2000 Division Pharmaceutical Liaison 2010-present Safety Committee 2023-present Research and Development Committee (2022–present)
- (2022–present)
- Boy Scouts of America; Greater Niagara Frontier Council, Advancement Committee (2009–2012)
- Boy Scout Troop #583; Assistant Scoutmaster (2004–2011)
- Cub Scout Pack #583; Assistant Cubmaster (2001–2004)
- Fellowship Program Director (2000–2023)